Table 2.
Comparison with other studies
| Studies | Our Study | Koshy et al.[16] | Gupta et al.[17] | Bagchi et al.[16] | Kohli et al.[7] | Prakash et al.[6] |
|---|---|---|---|---|---|---|
| Patients (n) | 230 | 231 | 109 | 124 | 26 | 65(only glomerular diseases) |
| Duration of study | 2012–2017 | 2010–2016 | 2011–2014 | 2010–2014 | 200–2004 | 1998–2002 |
| Proportion of total biopsies done in the study period (%) | 13.8% | 33% | 8.7% | 7.2% | 12.4% | NA |
| Age (years) (mean±SD) | 64.02±7.87 | 64±6.03 | 67.7±6.4 | 64.9±4.9 | 63.5±3.2 | 64.2±0.83 |
| Age (years) cutoff | ≥60 years | ≥60 years | ≥60 years | ≥60 years | ≥60 years | ≥60 years |
| Common indications for biopsy | NS (49.6%) RPRF (20.9%) AKI (15.7%) |
NS (30.4%) Nephritic Syndrome (19.1%) AKI (15.7%) |
NS (37.4%) RPRF Nephritic syndrome |
NS (39.5%) AKI/RPGN (32.3%) |
AKI/RPRF (73%) NS (27%) |
NS (61.5%) Nephritic syndrome (29.2%) RPGN (6.15%) |
| Most common histology in NS | MGN | MGN | Amyloidosis | MGN | MGN, Amyloidosis | MGN |
| Most common histology in RPRF/AKI/Nephritic | RPRF-Crescentic GN AKI-ATN Nephritic-MPGN, DPGN |
RPRF-PIGN AKI- AIN Nephritic-Benign Nephrosclerosis |
RPRF-Pauci-immune crescentic GN, Nephritic-MPGN |
AKI/RPRF: Pauci-immune crescentic GN | NA | NA |
| Most common histology overall | MGN (15.2%) Amyloidosis (13.9%) AKI (13%) |
Diabetic Nephropathy (14.3%) CTIN (11.3%) MGN (10.4%) |
NA | MGN (22.6%) FSGS (12.9%) MCD (11.3%) |
Crescentic GN, AIN | NA |
AKI: Acute kidney injury, AIN: Acute interstitial nephritis, ATN: Acute tubular necrosis, CGN: Chronic glomerulonephritis, CTIN: Chronic tubulointerstitial nephritis, DPGN: Diffuse proliferative, FSGS: Focal segmental glomerulosclerosis, GN: Glomerulonephritis, MCD: Minimal change disease, MGN: Membranous nephropathy, MIDD: Monoclonal immunoglobulin deposition diseases, glomerulonephritis, MPGN: Membranoproliferative glomerulonephritis, NS: Nephrotic syndrome, PIGN: Post-infectious glomerulonephritis, RPGN: Rapidly progressive glomerulonephritis, RPRF: Rapidly progressive renal failure, TMA: Thrombotic microangiopathy, NA: Data not available